Attributes that support an IPO exit:
• Proof-of-concept clinical data on lead drug candidate - typically robust Phase IIb or later data that provide substantial evidence of efficacy and safety.
• Legacy pharmaceutical partner to provide validation.
• Defined near- to intermediate-term news flow, with clear data points and events that will drive stock price accretion for new investors.
• Drug candidate that addresses large potential market opportunity
Picking the Right Exit
Picking the right exit By Sam Hall and Alastair J.J. Wood Illustrations by Tomasz Walenta Attributes that support an IPO exit: • Proof-of-concept clinical data on lead drug candidate - typically robust Phase IIb or later data that provide substantial evidence of efficacy and safety. • Legacy pharmaceutical partner to provide validation. • Defined near- to intermediate-term news flow, with clear data points and events that will drive stock price ac
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Meet the Author
Sam Hall
This person does not yet have a bio.View full profileAlastair J.J. Wood
This person does not yet have a bio.View full profile
Published In
Share
